Skip to NavigationSkip to content

BioInvent receives $3m payment for antibodies selected by Pfizer

Published on 23/12/20 at 11:43am

BioInvent International, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, has announced that Pfizer has selected antibodies directed at a previously-selected target under the companies' cancer immunotherapy research collaboration and licence agreement.

The agreement, into which the companies entered in December 2016, covers developing antibodies from BioInvent's proprietary F.I.R.S.TTM drug discovery platform targeting tumour-associated myeloid cells.

The selection of these antibodies triggers a payment of $3 million from Pfizer to BioInvent, and BioInvent is eligible for further milestone payments from development of these antibodies and potential selection and development of further antibodies directed at the same target.

Martin Welschof, BioInvent's CEO, said: “Pfizer's selection of antibodies under our agreement is a great demonstration of the actionable leads generated by our drug discovery technology platform. We are very pleased with how our partnership is progressing and look forward to further strengthening our collaboration.

“Our F.I.R.S.TTM platform is a patient-centric approach, drawing on our high-quality n-CoDeR antibody library to produce promising drug candidates, and we believe this partnership is an important validation of this technology.”

Darcy Jimenez

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches